Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AAV-based Gene Therapy
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Spur Therapeutics
Deal Size : $0.6 million
Deal Type : Agreement
Details : Under the terms of the agreement, Freeline gains rights to develop and commercialise AAV-based gene therapies for certain cardiac conditions using key targets identified by Forcefield.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 04, 2023
Lead Product(s) : AAV-based Gene Therapy
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Spur Therapeutics
Deal Size : $0.6 million
Deal Type : Agreement
Lead Product(s) : Chrdl1
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Positive preclinical data of Chrdl1 in Science Translational Medicine, published today, outlines the mechanisms of the three proteins, which have been shown to restore heart function following a heart attack in mice.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 31, 2022
Lead Product(s) : Chrdl1
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
